| Literature DB >> 29924187 |
Daniel Jose Szor1, Andre Roncon Dias1, Marina Alessandra Pereira1, Marcus Fernando Kodama Pertille Ramos1, Bruno Zilberstein1, Ivan Cecconello1, Ulysses Ribeiro-Júnior1.
Abstract
High levels of inflammatory markers and the neutrophil-lymphocyte ratio appear to be associated with worse overall survival in solid tumors. However, few studies have analyzed the role of the neutrophil-lymphocyte ratio in gastric cancer patients scheduled to undergo curative resection. In the present study, a systematic review and meta-analysis was performed to analyze the relationship between the neutrophil-lymphocyte ratio and overall survival in patients with gastric cancer submitted to curative resection and to identify the clinicopathological features (age, gender, tumor depth, nodal involvement and tumor differentiation) that are correlated with high neutrophil-lymphocyte ratios. A literature search of PubMed, Scopus, Cochrane and EMBASE through November 2017 was conducted. Articles that included gastric cancer patients submitted to curative resection and preoperatory neutrophil-lymphocyte ratio values were included. A total of 7 studies comprising 3264 patients from 5 different countries were included. The meta-analysis revealed an association of high neutrophil-lymphocyte ratios with older age, male gender, lower 5-year overall survival, increased depth of tumor invasion, positive nodal involvement but not with histological differentiation. Evaluation of the neutrophil-lymphocyte ratio is a cost-effective method that is widely available in preoperatory settings. Furthermore, it can effectively predict prognosis, as high values of this biomarker are related to more aggressive tumor characteristics. This ratio can also be used to stratify risk in patients within the same disease stage and may be used to assist in individualized follow-up and treatment.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29924187 PMCID: PMC5996440 DOI: 10.6061/clinics/2018/e360
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1Literature screening flow chart and results.
Quality assessment of included articles based on the Newcastle-Ottawa Scale.
| Name | A | B | C | D | E | F | G | H | Score |
|---|---|---|---|---|---|---|---|---|---|
| * | * | * | * | * | * | * | 7 | ||
| * | * | * | * | * | * | * | 7 | ||
| * | * | * | * | * | * | * | 7 | ||
| * | * | * | * | * | * | 6 | |||
| * | * | * | * | * | * | 6 | |||
| * | * | * | * | * | * | * | 7 | ||
| * | * | * | * | * | * | * | * | 8 |
A. Representativeness of the exposed cohort; B. Selection of the non-exposed cohort; C. Determination of exposure; D. Demonstration that outcome of interest was not present at the start of the study; E. Comparability of cohorts on the basis of the design analysis; F. Assessment of outcome; G. Sufficient follow-up duration to measure outcomes; H. Adequacy of follow-up cohorts.
Characteristics of the included studies.
| n | Age (yrs) | Study design | NLR cutoff | Type | % high | Country | Median follow-up (months) | Blood sample | Neoadjuvant | OS 5 yrs low vs high (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220 | 57 (23-89) | retrospective | 2.15 | 75th percentile | 25.4 | Korea | NA | Before surgery | NA | 74.4 | |
| 162 | 56 (31-82) | retrospective | 4.02 | Median | 47.5 | China | NA | Before surgery | NA | 48.5 | |
| 156 | 74 (39-91) | retrospective | 2.34 | Median | 51.2 | Italy | 23 | Day before surgery | Yes (18) | 67 | |
| 291 | NA | retrospective | 3.5 | NA | 45 | China | NA | Week Before surgery | No | 43.6 | |
| 1028 | 65 (26-89) | prospective | 4 | NA | 12.4 | Japan | 23 | Before surgery | NA | 81 | |
| 1030 | NA | retrospective | 3.44 | NA | 52.8 | Taiwan | 30 | Before surgery | No | 64.1 | |
| 377 | 64 (25-80) | retrospective | 1.4 | ROC analysis | 81.9 | China | 42 | Day before surgery | No | 63.2 |
NA: not available.
Figure 2NLR and age.
Figure 3NLR and gender.
Figure 4NLR and pT status (pT3 and pT4).
Figure 5NLR and lymph node involvement.
Figure 6NLR and tumor differentiation grades.
Figure 7NLR and overall survival.